Chugai Announced New Mid-Term “Sunrise 2012” Plan
This article was originally published in PharmAsia News
Chugai President Naoru Nagayama announced a new mid-term business plan, Sunrise 2012, at a Jan. 30 briefing to stave off a lowered profit target from ¥100 billion to ¥80 billion. He said he is still optimistic about maximum value generation from the company's new products, and that its alliance with Roche has reinforced its cancer drug pipeline. In 2007, three new products - Avastin, Tarceva and Copegus went on sale. Chugai's IL-6 receptor antibody Actemra also was submitted for approval overseas. Nagayama said these developments indicated the portfolio is bearing fruit. Chugai will also strengthen marketing and sales operations, and will set up a portfolio management committee and strategic marketing committee, aiming to defend market shares for current products and realize maximum valuation for new cancer treatments. (Click for more-Japanese language
You may also be interested in...
The UK's Advertising Standards Authority will closely monitor the marketing communications of dietary supplements e-tailer Health Solutions after it failed to provide a substantive response to health claims regulation breaches.
Consensus report CR511 from the Association for the Advancement of Medical Instrumentation highlights common system elements for engineers, and outlines safety and risk-control measures that manufacturers and caregivers should consider.
The EU pharmaceutical strategy published on 25 November will be the first step in a “complete overhaul” of the medicines legislative framework to be proposed in about two years’ time, says the European Commission.